Macrocyclic HCV Inhibitors Resolving Efficacy and Resistance Trade-offs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HCV therapies face challenges such as limited efficacy, significant side effects, emergence of drug-resistant mutants, and compliance issues due to sub-optimal pharmacokinetics and complex dosage regimes, necessitating the development of more effective and tolerable treatments with improved resistance profiles and pharmacokinetics.
Innovation Solution
Development of macrocyclic compounds represented by formula (I) and their derivatives, which exhibit enhanced potency, decreased cytotoxicity, improved pharmacokinetics, and resistance profiles, as well as ease of synthesis from commercially available starting materials, for use as inhibitors of HCV replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HCV therapies (interferon-alpha and ribavirin) are used, then treatment coverage is achieved, but side effects are significant and efficacy is limited
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure from traditional peptidomimetic inhibitors to macrocyclic compounds with specific ring structures (14-20 membered rings). This structural parameter change results in improved pharmacokinetic properties, enhanced potency against HCV protease, and reduced side effects compared to existing therapies.
Solution Approach 2:
The macrocyclic compounds represent a composite structural approach, combining multiple functional groups (amides, esters, heterocyclic rings) within a cyclic framework. This composite structure provides both high antiviral activity and improved safety profile by integrating multiple pharmacophores into a single molecular entity.
2Reliability
If peptidomimetic HCV protease inhibitors are administered, then antiviral activity is achieved, but drug-resistant mutants emerge
Solution Approach 1:
The patent changes the fundamental parameter of inhibitor structure from linear peptidomimetics to cyclic macrostructures. This parameter change creates a new resistance profile by introducing steric constraints and alternative binding modes that prevent the development of common resistance mutations observed with linear inhibitors.
Solution Approach 2:
The macrocyclic structure introduces curvature and three-dimensional rigidity to the inhibitor molecule. This spheroidal/cyclic geometry creates a more stable binding interaction with the protease active site, reducing the likelihood of resistance development through conformational adaptation.
3Reliability
If complex dosage regimes are implemented, then therapeutic control is achieved, but compliance becomes difficult
Solution Approach 1:
The patent changes pharmacokinetic parameters through macrocyclic structure design, achieving improved oral bioavailability, extended half-life, and sustained plasma concentrations. These parameter changes enable simpler dosing regimens (e.g., once-daily or less frequent dosing) while maintaining effective therapeutic control.
4Ease of operation
If sub-optimal pharmacokinetics are present, then drug delivery is simplified, but therapeutic effectiveness decreases
Solution Approach 1:
The macrocyclic structure fundamentally changes pharmacokinetic parameters including absorption, distribution, metabolism, and excretion (ADME) properties. The cyclic framework provides metabolic stability against proteolytic degradation, improves oral bioavailability, and extends half-life, thereby enhancing therapeutic effectiveness without complicating delivery.
Data Source
AI summary
Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is -OR6, -NH-SO2R7; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; n is 3, 4, 5, or 6; R4 and R5 taken together with the nitrogen atom to which they are attached form a bicyclic ring system selected from formula (II) wherein said ring system may optionally be substituted with 1-3 substituents; R6 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R7 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each of which may be optionally substituted with 1-3 substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from N, O or S, and being optionally substituted with 1-3 substituents pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.